Fairvalue-Calculator Fairvalue-Calculator
EN DE

Enzymatica AB (ENZY) Fair Value & Analysis

Healthcare · SE · Market cap 682M SEK

Pricekr 2.13
Fair Valuekr 2.30
Upside+8.0%
Quality95/100
Evidence: Low Range kr 1.73 – kr 2.88

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Enzymatica AB (ENZY) currently trades at kr 2.13, while our model-based Fair Value estimate is kr 2.30 — implying the stock looks roughly 8.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Enzymatica AB (ENZY) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 2.30 versus a price of kr 2.13 — about +8% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ENZY?
Our 21-model fair value for Enzymatica AB is kr 2.30 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 2.13.
What is the quality score of ENZY?
Enzymatica AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.